Evolent Health (EVH)
(Delayed Data from NYSE)
$27.65 USD
-0.67 (-2.37%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $27.65 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth A Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
EVH 27.65 -0.67(-2.37%)
Will EVH be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for EVH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EVH
Does Evolent Health (EVH) Have the Potential to Rally 34.46% as Wall Street Analysts Expect?
Wall Street Analysts Predict a 35.7% Upside in Evolent Health (EVH): Here's What You Should Know
EVH: What are Zacks experts saying now?
Zacks Private Portfolio Services
New Strong Buy Stocks for January 5th
How Much Upside is Left in Evolent Health (EVH)? Wall Street Analysts Think 59.66%
Best Momentum Stocks to Buy for November 20th
Other News for EVH
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Evolent Health (EVH) and BioMarin Pharmaceutical (BMRN)
Evolent Health initiated with bullish view at Citi, here's why
In-Depth Examination Of 6 Analyst Recommendations For Evolent Health
Evolent To Release First Quarter 2024 Financial Results on Thursday, May 9, 2024
Analysts’ Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)